Publications by authors named "G Gauler"
Background: Safety recommendations for Janus kinase inhibitors (JAKi) issued by the European Medical Agency (EMA) in 2023 could potentially influence treatment patterns for rheumatoid arthritis (RA) drugs, but little is known about the impact of these recommendations in routine clinical care.
Methods: We retrospectively analyzed the German RHADAR rheumatology database for adult patients with RA and documentation of a new therapy with a JAKi, tumor necrosis factor inhibitor (TNFi), or interleukin-6 receptor inhibitor (IL-6Ri). Data were grouped into half-yearly intervals from quarter (Q)2/2020 to Q3/2023.
Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network.
Patrick-Pascal Strunz Matthias Englbrecht Linus Maximilian Risser Torsten Witte Matthias Froehlich Georg Gauler
Rheumatol Int
October 2024
Article Synopsis
- Janus kinase inhibitors (JAKi) have recently been approved alongside tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i) as treatment options for axial spondyloarthritis (axSpA), yet their real-world drug survival is under-studied.
- A retrospective analysis of 1,222 axSpA patients, focusing on treatment initiation timing from January 2015 to October 2023, reveals median drug survival rates of 31 months for TNFi, 25 months for IL-17i, and 18 months for JAKi.
- Higher discontinuation rates were seen for JAKi and IL-17i compared to TNFi, with
Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database.
Patrick-Pascal Strunz Matthias Englbrecht Linus Maximilian Risser Torsten Witte Matthias Froehlich Georg Gauler
Front Immunol
June 2024
Article Synopsis
- Treatment options for psoriatic arthritis have expanded to include various biologic DMARDs and Janus kinase inhibitors, but real-world data on their persistence in patients is limited.
- A study analyzed 1352 prescriptions and found that the 5-year survival rates were highest for IL-17 inhibitors (67.8%) and lowest for IL-12/23 inhibitors (46.0%), with JAKi showing a higher likelihood of discontinuation.
- The findings suggest that patients in Germany may stick with TNFi and IL-17i longer than IL-12/23i or JAKi, potentially influenced by disease severity and other health conditions like osteoarthritis.
Article Synopsis
- The study explored the differentiation between radiographic (r-axSpA) and non-radiographic (nr-axSpA) axial spondyloarthritis in a real-world clinical setting, analyzing data from 371 patients in Germany.
- Findings showed that nearly half of the patients were classified as having definite r-axSpA, with those in this category receiving more aggressive treatment options like disease-modifying antirheumatic drugs (DMARDs) compared to nr-axSpA patients.
- The availability of radiographic imaging was limited, with only about 58% of patients having the necessary imaging documentation, and follow-up imaging was rare; however, it confirmed r-axSpA in approximately 40
Article Synopsis
- The study highlights that 80% of rheumatoid arthritis (RA) patients have at least one comorbidity, with high rates of depression and anxiety compared to the general population, prompting the need for effective screening and care.
- A year-long randomized controlled trial involving 224 patients tested the effects of team-based care on managing depression and anxiety, focusing on an intervention group (IG) receiving support from rheumatological assistants.
- Results indicated significant improvements in anxiety symptoms and patient satisfaction in the IG, demonstrating the benefits of collaborative care, while no significant changes in depression levels were observed.